# US 2013/0252267 A1 · Urine and serum biomarkers associated with diabetic nephropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252267 A1
- Document ID: US20130252267A1
- Status: Published application
- Kind: A1
- Application number: 13/901,819
- Filed: 2013-05-24
- Published: 2013-09-26
- Earliest claimed: 2009-01-28
- Assignees: Bio Preventive Medicine Corp.
- Applicants: Industrial Technology Research Institute
- Inventors: Wei-Ya Lin; Mary Ya-Ping Yeh; Tzu-Ling Tseng; Ping-Fu Cheng; Tsai-Wei Hsu; Hung-Yi Li; Yi-Ting Chen; Yuh-Feng Ling; Jin-Shuen Chen; Yen-Peng Li
- Web page: https://patentgrep.com/patent/US20130252267A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/4728: alpha-Glycoproteins
- G01N 2333/52: Assays involving cytokines
- G01N 2333/71: for growth factors; for growth regulators
- G01N 2333/8125: Alpha-1-antitrypsin
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described are uses of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.

## Claims

### Claim 1

A method of diagnosing diabetic nephropathy in a subject, comprising:
determining in a subject suspected of having diabetic nephropathy a level of a biomarker selected from the group consisting of:
(i) a first urine protein molecule that is precursor alpha-2-HS-glycoprotein or a fragment thereof having at least ten amino acid residues,
(ii) a second urine protein molecule that is alpha-1 antitrypsin or a fragment thereof having at least ten amino acid residues,
(iii) a third urine protein molecule that is a fragment of alpha-1 acid glycoprotein having at least ten amino acid residues, and
(iv) a serum protein molecule that is osteopontin or a fragment thereof having at least ten amino acid residues, and
assessing whether the subject has diabetic nephropathy based on the level of the biomarker;
wherein an increase in the level of the biomarker, as compared to that in a diabetic nephropathy-free subject, indicates that the subject has diabetic nephropathy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fragment of precursor alpha-2-HS-glycoprotein is mature alpha-2-HS-glycoprotein, VVSLGSPSGEVSHPRKT (SEQ ID NO:1), or MGVVSLGSPSGEVSHPRKT (SEQ ID NO:2).

### Claim 3 (depends on 1)

The method of claim 1, wherein the fragment of alpha-1 antitrypsin is KGKWERPFEVKDTEEEDF (SEQ ID NO:3), MIEQNTKSPLFMGKVVNPTQK (SEQ ID NO:4), EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAE (SEQ ID NO:5), or EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFA (SEQ ID NO:6)

### Claim 4 (depends on 1)

The method of claim 1, further comprising, after the assessing step, correlating the level of the biomarker with diabetic nephropathy status based on pre-determined reference levels of the biomarker representing early and late stage diabetic nephropathy.

### Claim 5 (depends on 1)

The method of claim 1, wherein the third urine protein molecule is GQEHFAHLLILRDTKTYMLAFDVNDEKNWGLS (SEQ ID NO:7).

### Claim 6 (depends on 1)

The method of claim 1, wherein the fragment of osteopontin is YPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSK (SEQ ID NO:8) or KYPDAVATWLNPDPSQKQNLLAPQTLPSK (SEQ ID NO:9).

### Claim 7

A method for assessing efficacy of a diabetic nephropathy treatment in a subject, comprising:
determining in the subject a pre-treatment level of a biomarker selected from the group consisting of
(i) a first urine protein molecule that is precursor alpha-2-HS-glycoprotein or a fragment thereof having at least ten amino acid residues,
(ii) a second urine protein molecule that is alpha-1 antitrypsin or a fragment thereof having at least ten amino acid residues,
(iii) a third urine protein molecule that is a fragment of alpha-1 acid glycoprotein having at least ten amino acid residues, and
(iv) a serum protein molecule that is osteopontin or a fragment thereof having at least ten amino acid residues;
determining in the patient a post-treatment level of the biomarker; and
assessing efficacy of the treatment based on a change in the level of the biomarker after the treatment,
wherein the post-treatment level of the biomarker being the same or lower than the pre-treatment level of the biomarker indicates effectiveness of the treatment.

### Claim 8 (depends on 7)

The method of claim 7, wherein:
the fragment of precursor alpha-2-HS-glycoprotein is mature alpha-2-HS-glycoprotein, VVSLGSPSGEVSHPRKT (SEQ ID NO:1), or MGVVSLGSPSGEVSHPRKT (SEQ ID NO:2);
the fragment of alpha-1 antitrypsin is KGKWERPFEVKDTEEEDF (SEQ ID NO:3), MIEQNTKSPLFMGKVVNPTQK (SEQ ID NO:4), EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAE (SEQ ID NO:5), or EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFA (SEQ ID NO:6);
the fragment of alpha-1 acid glycoprotein is GQEHFAHLLILRDTKTYMLAFDVNDEKNWGLS (SEQ ID NO:7); and
the fragment of osteopontin is YPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSK (SEQ ID NO:8) or KYPDAVATWLNPDPSQKQNLLAPQTLPSK (SEQ ID NO:9).

### Claim 9

A method for determining a diabetic nephropathy stage in a subject, comprising:
obtaining a urine sample and, optionally, a serum sample from a subject suspected of having diabetic nephropathy;
determining in the sample(s) a level of a biomarker composed of at least two protein molecules and, optionally, one or more clinical factors, wherein the at least two protein molecules are selected from the group consisting of five protein molecules:
(i) a first urine protein molecule that is precursor alpha-2-HS-glycoprotein or a fragment thereof having at least ten amino acid residues,
(ii) a second urine protein molecule that is alpha-1 antitrypsin or a fragment thereof having at least ten amino acid residues,
(iii) a third urine protein molecule that is alpha-1 acid glycoprotein or a fragment thereof having at least ten amino acid residues,
(iv) a serum protein molecule that is osteopontin or a fragment thereof having at least ten amino acid residues, and
(v) a fourth urine protein molecule that is osteopontin or a fragment thereof having at least ten amino acid residues,
and the clinical factors are selected from the group consisting of age, gender, HbA1c, albumin creatinine ratio, and glomerular filtration rate;
calculating a disease score based on the level of the biomarker; and
assessing the subject's diabetic nephropathy stage based on the disease score as compared to pre-determined cutoff values indicating different diabetic nephropathy stages.

### Claim 10 (depends on 9)

The method of claim 9, wherein the disease score is calculated by an analysis selected from the group consisting of ridge regression analysis, factor analysis, discriminant function analysis, and logistic regression analysis.

### Claim 11 (depends on 9)

The method of claim 9, wherein:
the fragment of precursor alpha-2-HS-glycoprotein is mature alpha-2-HS-glycoprotein, VVSLGSPSGEVSHPRKT (SEQ ID NO:1), or MGVVSLGSPSGEVSHPRKT (SEQ ID NO:2);
the fragment of alpha-1 antitrypsin is KGKWERPFEVKDTEEEDF (SEQ ID NO:3), MIEQNTKSPLFMGKVVNPTQK (SEQ ID NO:4), EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAE (SEQ ID NO:5), or EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFA (SEQ ID NO:6);
the fragment of alpha-1 acid glycoprotein is GQEHFAHLLILRDTKTYMLAFDVNDEKNWGLS (SEQ ID NO:7); and
the fragment of osteopontin is YPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSK (SEQ ID NO:8) or KYPDAVATWLNPDPSQKQNLLAPQTLPSK (SEQ ID NO:9).

### Claim 12 (depends on 9)

The method of claim 9, wherein the obtaining step is performed by collecting both a urine sample and a serum sample and the biomarker is composed of all of protein molecules (i)-(v).

### Claim 13 (depends on 9)

The method of claim 9, wherein the obtaining step is performed by collecting a urine sample and the biomarker is composed of at least two of protein molecules (i)-(iii) and (v).

### Claim 15

A kit for diagnosing diabetic nephropathy, comprising two, three, or four antibodies, each of which is capable of binding to (i) alpha-2-HS-glycoprotein, (ii) alpha-1 antitrypsin, (iii) alpha-1 acid glycoprotein, or (iv) osteopontin, wherein the two, three, or four antibodies have different antigen specificities.

### Claim 16 (depends on 15)

The kit of claim 15, wherein the antibodies are whole immunoglobulin molecules.

### Claim 17 (depends on 15)

The kit of claim 15, wherein the two, three, or four antibodies are selected from antibodies that each specifically bind to one of the following peptides:
(SEQ ID NO: 2)
MGVVSLGSPSGEVSHPRKT,
(SEQ ID NO: 3)
KGKWERPFEVKDTEEEDF,
(SEQ ID NO: 4)
MIEQNTKSPLFMGKVVNPTQK,
(SEQ ID NO: 6)
EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFA,
(SEQ ID NO: 7)
GQEHFAHLLILRDTKTYMLADVNDEKNWGLS,
(SEQ ID NO: 8)
YPDAVATWLNPDPSQKQ NLLAPQNAVSSEETNDFKQETLPSK,
and
(SEQ ID NO: 9)
KYPDAVATWLNPDPSQKQNLLAPQTLPSK.

### Claim 18 (depends on 15)

The kit of claim 15, consisting essentially of two, three, or four antibodies, each of which is capable of binding to (i) alpha-2-HS-glycoprotein, (ii) alpha-1 antitrypsin, (iii) alpha-1 acid glycoprotein, or (iv) osteopontin, wherein the two, three, or four antibodies have different antigen specificities.
